Extended OC use may relieve PMS
December 1st 2006Taking a continuous 168-day course of oral contraceptives (OCs) can reduce symptoms of premenstrual syndrome, or PMS, compared to the 21/7-day regimen, according to the results of a study published in the November issue of the American Journal of Obstetrics and Gynecology.
UAE linked to pregnancy risks, incuding preterm and CD
December 1st 2006Women who have undergone uterine artery embolization (UAE) to treat fibroids have a significantly higher risk of delivery by cesarean section as well as an increase in preterm delivery, postpartum hemorrhage, miscarriage, and lower pregnancy rates compared to the general obstetric population, according to study findings published in the November issue of the American Journal of Obstetrics and Gynecology
Gestational Hypertension: Implications for Pre-eclampsia and Eclampsia
Experts discuss potential complications of gestational hypertension, as well as the role of home blood-pressure (BP) monitoring as an adjunct in managing these cases.
The Management of Infertility Associated With Polycystic Ovary Syndrome
November 14th 2006Polycystic ovary syndrome [PCOS] is the commonest cause of anovulatory infertility. Treatment modes available are numerous mainly relying on ovarian stimulation with FSH, a reduction in insulin concentrations and a decrease in LH levels as the basis of the therapeutic principles.
Leveling with patients about the risks of ART
November 1st 2006Be frank about the real and potential complications when counseling patients considering assisted reproductive technologies. The list includes the link between multiple gestations and preterm delivery, the possibility of ectopic pregnancies or malformations-and much more.
Drospirenone/E2 reduces BP in postmenopausal women with hypertension
November 1st 2006Hormonal therapy with drospirenone plus estradiol (E?) lowers blood pressure and spares potassium in postmenopausal women on hydrochlorothiazide (HCTZ). So say results of a small randomized, placebo-controlled trial presented at the 17th annual NAMS meeting.
Sign Out: When 'show and tell' is serious medicine
November 1st 2006Do you remember bringing something to school for "show and tell" when you were a child? That's what I did recently, only it wasn't a game. I was teaching basic medicine, obstetrics, and gynecology to medical students, lay midwives, and physicians in Liberia.
Leveling with patients about the risks of ART
November 1st 2006Be frank about the real and potential complications when counseling patients considering assisted reproductive technologies. The list includes the link between multiple gestations and preterm delivery, the possibility of ectopic pregnancies or malformations-and much more.
Aromatase inhibitors: The next wave in treatment of endometriosis?
November 1st 2006Blocking the activity of aromatase may be the key to controlling the often-intractable pain of endometriosis. Here, pioneers in the use of aromatase inhibitors review use of the drugs in premenopausal and postmenopausal patients.
Ultrasound Clinics: Nuchal translucency assessment: What else can it tell us?
November 1st 2006Data from the FASTER and BUN trials show that first-trimester NT measurement can reveal a lot more than just trisomy 21. Although not ready for prime time as a screening test for congenital heart disease, we can't ignore the strong association between increased NT and an elevated risk of several cardiac birth defects and to a lesser degree diaphragmatic hernia. But what can we do about it?
Michigan court says MDs can sue for unfair peer review
November 1st 2006Thanks to a ruling by Michigan's Supreme Court, physicians in the state may now sue hospitals and peer review committees for wrongful peer review. The high court's ruling overturns almost 25-year-old case law, which kept courts from getting involved in hospitals' staffing decisions because of its lack of expertise. As a result, physicians' claims of unfair peer review were often rejected.
Bisphosphonates reduce costs-if women take them
November 1st 2006Osteoporosis-related health-care costs are lower for postmenopausal women prescribed bisphosphonates-if they comply with therapy. That is the conclusion of a retrospective analysis of prescription and treatment data presented at this year's NAMS meeting.